Kineret was launched in 2002 by Amgen, and licensed from Amgen by Sobi in 2008 for worldwide exclusive licensing.
What was once touted as a promising novel IL-1 blockade therapy for the treatment of moderate to severely active RA has turned into a rarely used RA therapy.